Colin Anderson Productions pty ltd
AbbVie (NYSE:ABBV) reported initial findings from two studies in the late-stage trial of its experimental drug, Rinvoq (upadacitinib), for adults and adolescents suffering from severe alopecia areata.
In the second study, both 15 mg and 30 mg doses of upadacitinib met the main goal.
Specifically, 44.6% of patients taking the 15 mg dose and 54.3% of those on the 30 mg dose achieved 80% or more scalp hair coverage after 24 weeks. In contrast, only 3.4% of patients who received a placebo reached this level of hair coverage.
In the trial, the secondary goals were also achieved. These included improvements in eyebrow and eyelash hair, as well as the percentage of participants who had 90% or more scalp coverage and those with complete scalp hair coverage at the 24-week mark.
The company said that the safety profile observed in patients with alopecia areata was generally in line with what has been seen in other approved uses of the drug, and no new safety concerns were raised during this study.